Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutation-positive NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT07838532
What this trial is testing

Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC

Who this might be right for
Non Small Cell Lung CancerT790MEGFR Activating Mutation
Xin Li 637
Testing effectiveness (Phase 2)Looking for participantsNCT07295821
What this trial is testing

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

Who this might be right for
Lung Cancer
AstraZeneca 60
Testing effectiveness (Phase 2)Looking for participantsNCT06775743
What this trial is testing

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT04027647
What this trial is testing

Phase 2 Study of Dacomitinib in NSCLC

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IIICNSCLC Stage IV+2 more
National Cancer Centre, Singapore 118
Not applicableApproved For MarketingNCT04829422
What this trial is testing

Early Access Program of Lazertinib in Republic of Korea

Who this might be right for
Lung Cancer
Yuhan Corporation
Not applicableStudy completedNCT02131259
What this trial is testing

Long-term Observation PMS for Afatinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,605
Not applicableStudy completedNCT04552613
What this trial is testing

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

Who this might be right for
Non-small-lung-cell CancerNSCLCEGFR Gene Mutation
The Fourth Affiliated Hospital of Zhejiang University School of Medicine 114
Testing effectiveness (Phase 2)Looking for participantsNCT05104788
What this trial is testing

Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Peking University Cancer Hospital & Institute 27
Testing effectiveness (Phase 2)Study completedNCT01982955
What this trial is testing

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Who this might be right for
Non-small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany 88
Not applicableWithdrawnNCT02368990
What this trial is testing

T790M Mutation Positive 2nd Line STandard of cAre Registry

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca
Not applicableStudy completedNCT01790217
What this trial is testing

An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06319950
What this trial is testing

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Who this might be right for
Lung Cancer, Nonsmall Cell
Taizhou Hospital 255
Testing effectiveness (Phase 2)Study completedNCT04563871
What this trial is testing

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Sehhoon Park 73
Large-scale testing (Phase 3)Not Yet RecruitingNCT06048315
What this trial is testing

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Who this might be right for
Lung CancerTKI ResistanceEGFR Sensitive Mutation+2 more
Degan Lu 52
Testing effectiveness (Phase 2)Looking for participantsNCT07375316
What this trial is testing

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy

Who this might be right for
Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials 120
Testing effectiveness (Phase 2)Study completedNCT03239340
What this trial is testing

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Who this might be right for
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 154
Not applicableNo Longer AvailableNCT02451852
What this trial is testing

AZD9291 US Expanded Access Program

Who this might be right for
EGFR T790M Mutation Positive NSCLC
AstraZeneca
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07285148
What this trial is testing

Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR MutationMetastatic Lung Cancer+1 more
Beijing Pearl Biotechnology Limited Liability Company 253
Large-scale testing (Phase 3)UnknownNCT02972333
What this trial is testing

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Who this might be right for
EGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more
Shandong Cancer Hospital and Institute 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07622706
What this trial is testing

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Who this might be right for
NSCLCEGFR Positive Non-small Cell Lung CancerNeoadjuvant Therapy
Peking University Cancer Hospital & Institute 60
Next Page